last authored: April 2012, David LaPierre
last reviewed:
Thrombotic Throbocytopenic Purpura (TTP) is a life-threatening syndrome characterized by thrombocytopenia (low platelets) and microangiopathic hemolytic anemia (MAHA). These abnormalities, which are believed to be related to abnormal enzyme function, can lead to thrombus (clot) formation in arterioles and organ damage.
The five classic symptoms of TTP are as follows:
TTP shares many similarities with hemolytic-uremic syndrome (HUS) in regards to clinical manifestations and pathophysiology, though they are believed to be different disease entities.
a simple case introducing clincial presentation and calling for a differential diagnosis to get students thinking.
As described under 'Pathophysiology', TTP is believed to be due to deficiency of metalloproteinase enzyme. This can be due to the following conditions:
von Willebrand factor (vWF) is secreted by endothelial cells in a large polymer. It is normally rapidly cleaved by ADAMTS-13, a metalloproteinase enzyme. However, in situations where ADAMTS-13 is defective or absent, vWF multimers lead to platelet aggregation. Endothelial damage can follow thrombus formation, which has the most significant effect on arterioles in the kidney, brain, pancrease, adrenals, and heart.
Congenital absence of ADAMTS-13 can lead to vWF aggregation. Other mechanisms of setting off this reaction include:
Symptoms begin acutely and are typically non-specific, including:
Neurological symptoms are present in up to 90% of cases, and can include:
Renal symptoms can include:
Thrombocytopenia and hemolysis can lead to:
Physical exam may reveal:
Renal failure: abnormal urinalyis, oliguria, ARF
CBC and
peripheral smear
Plasmapheresis and steroids are the treatments of choice. Plasma infusion should be given if plasmapheresis is not immediately available.
Do NOT give platelets, as this can increase rates of intravascular thrombosis.
TTP rates of mortality are 90% if untreated.
authors:
reviewers: